Sellers of the drugstore chain's stock have been aggressive for months and the overall technical picture is weak.
Top picks in the fast-growing medical products market.
A follow-up to our story in June.
The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.
The Fed also finds itself under pressure amid indications of a slowing U.S. economy
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.
MN looks like it could move higher and rally, but the uneven trading pattern tells me to look for easier set-ups.
The oncology company has had a strong run and all the technical signals indicate the move higher isn't over.
Let's check out the charts and indicators.